Patients taking liraglutide (Victoza, Novo Nordisk) were at increased risk for gallbladder and biliary tract-related events in the LEADER trial but the mechanisms are unclear, a post-hoc analysis has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback